EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Artificial intelligence in genitourinary pathology

Ankush U Patel iD, Anil V Parwani iD, Swati Satturwar iD

Histopathology · 2026-01 · 88 (1) · 353-373

DOI: 10.1111/his.70020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 12.12.2025. Verfasst von Ankush U Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University, Wexner Medical Center and James Cancer Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Pathology, Clinical. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) is now a practical, value‐generating tool in genitourinary (GU) pathology. Real‐world deployments report up to 65% time‐savings and multi‐million‐dollar returns on investment within 3 years at high‐volume centres. Across prostate, bladder, renal and testicular systems, contemporary algorithms equal or exceed expert accuracy for cancer detection, grading and prognostication. Foundation models trained on millions of whole‐slide images now match specialized organ‐specific tools without bespoke tuning. High AI–pathologist concordance is widely regarded as a surrogate marker of safety and clinical acceptability, yet no universally codified regulatory threshold for sensitivity, specificity or concordance has been issued. Because internationally recognized guidelines still omit detailed instructions for safe roll‐out and sustained performance, we distilled insights from real‐world deployments and pioneering pilot studies into two complementary roadmaps: the nine‐step VALIDATED framework, which focuses on governance and safety oversight, and the 11‐principle ORCHESTRATE blueprint, which guides day‐to‐day implementation. By 2030, we anticipate AI will automate ~80% of routine quantification, allowing pathologists to assume the role of diagnostic orchestrators who integrate multimodal data streams, helping offset a ~40% workforce shortfall and reducing inter‐observer variability across practice settings. This review distils the evidence, economics and practical guidance required for successful AI adoption in GU pathology. Institutions following the VALIDATED–ORCHESTRATE pathway can harness efficiency gains while maintaining diagnostic excellence and achieving positive ROI within 5 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligencePathology, ClinicalHumans

Stichwörter der Autor:innen

Gleason gradingORCHESTRATE frameworkROI pathologyVALIDATED frameworkartificial intelligencebladder cancercomputational pathologydiagnostic orchestratordigital transformationfoundation modelsgenitourinary pathologyprostate cancerrenal cancer

Autor:innen und Institutionen

  • The Ohio State University, Wexner Medical Center and James Cancer Center, Columbus, OH, USA.

ORCID-Profile: Ankush U Patel, Anil V Parwani, Swati Satturwar

Zitieren

APA

Patel, A. U., Parwani, A. V., & Satturwar, S. (2026). Artificial intelligence in genitourinary pathology. Histopathology, 88(1), 353-373. https://doi.org/10.1111/his.70020

Vancouver

Patel AU, Parwani AV, Satturwar S. Artificial intelligence in genitourinary pathology. Histopathology. 2026;88(1):353-373. doi:10.1111/his.70020

BibTeX
@article{Patel2026,
  author = {Patel, Ankush U and Parwani, Anil V and Satturwar, Swati},
  title = {Artificial intelligence in genitourinary pathology},
  journal = {Histopathology},
  year = {2026},
  volume = {88},
  number = {1},
  pages = {353--373},
  doi = {10.1111/his.70020}
}
Kostenlos starten →